Bellicum Pharmaceuticals (BLCM) 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Entity Information [Line Items]
Entity Registrant Name	Bellicum Pharmaceuticals, Inc.
Entity Central Index Key	1358403
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		26,378,474

Balance_Sheets

Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$183,638	$191,602
Accounts receivable	94	298
Prepaid expenses and other current assets	1,279	1,322
Total current assets	185,011	193,222
Property and equipment, net of accumulated depreciation	3,164	2,427
Other assets	97	145
ASSETS	188,272	195,794
Current liabilities:
Accounts payable	1,115	1,209
Accrued expenses	1,079	2,163
Deferred revenue	0	13
Current portion of deferred rent	26	97
Current portion of deferred manufacturing costs	428	154
Total current liabilities	2,648	3,636
Long-term liabilities:
Deferred rent	263	209
Deferred Manufacturing Costs	0	313
Total long-term liabilities	263	522
TOTAL LIABILITIES	2,911	4,158
Commitments and Contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 200,000,000 shares authorized at March 31, 2015 and December 31, 2014; 27,055,937 shares issued and 26,378,474 shares issued and outstanding; at March 31, 2015; 27,050,055 issued and 26,372,592 issued and outstanding at December 31, 2014	271	271
Treasury stock: 677,463 shares held at March 31, 2015 and December 31, 2014	-5,056	-5,056
Additional paid-in capital	310,848	309,365
Accumulated deficit	-120,702	-112,944
Total stockholders’ equity	185,361	191,636
LIABILITIES AND STOCKHOLDERS’ EQUITY	$188,272	$195,794

Balance_Sheets_Balance_Sheet_P

Balance Sheets Balance Sheet Parenthetical (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$0.01	$0.01
Common stock, authorized (shares)	200,000,000	200,000,000
Common stock, issued (shares)	27,055,937	27,050,055
Common stock, outstanding (shares)	26,378,474	26,372,592
Treasury Stock, shares (shares)	677,463	677,463

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Grants	$107,000	$552,000
Total revenues	107,000	552,000
OPERATING EXPENSES	7,915,000	2,829,000
Research and development	5,718,000	2,389,000
General and administrative	2,197,000	440,000
Loss from operations	-7,808,000	-2,277,000
Interest income	50,000	3,000
Interest expense	0	-16,000
Total other income (expense)	50,000	-13,000
NET LOSS	-7,758,000	-2,290,000
Preferred stock dividends	0	-540,000
Net loss attributable to common shareholders, basic and diluted	($7,758,000)	($2,830,000)
Net loss per common share attributable to common shareholders, basic and diluted	($0.30)	($1.52)
Weighted-average shares outstanding, basic and diluted	26,259,392	1,863,350

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss	($7,758)	($2,290)
Depreciation expense	196	159
Share-based compensation	1,489	76
Amortization of lease liability	-17	-28
Accounts receivable	204	-527
Prepaid expenses and other current assets	91	17
Accounts payable	-94	-106
Accrued liabilities	-1,176	-581
Deferred costs	-52	62
Other liabilities	92	0
NET CASH USED IN OPERATING ACTIVITIES	-7,025	-3,218
Purchases of property and equipment	-933	-22
CASH USED IN INVESTING ACTIVITIES	-933	-22
Proceeds from exercise of stock options	2	0
Proceeds from issuance of Series B preferred stock	0	7,320
Payment of issuance costs of common stock	-8	0
Proceeds from exercise of common warrants	0	201
Payments on line of credit	0	-100
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES	-6	7,421
NET CHANGE IN CASH AND CASH EQUIVALENTS	-7,964	4,181
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	183,638	15,349
Dividends accrued on preferred stock	$0	$540

Organization_and_Business_Desc

Organization and Business Description (Notes)	3 Months Ended
	Mar. 31, 2015
Organization and Business Description [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	ORGANIZATION AND BUSINESS DESCRIPTION
	Bellicum Pharmaceuticals, Inc. (the Company or Bellicum), was incorporated in Delaware in July 2004 and is based in Houston, Texas. The Company is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is devoting substantially all of its present efforts to developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including, hematopoietic stem cell transplantation, CAR-T cell therapy and dendritic cell vaccines. The Company has not generated any revenue from product sales to date and does not anticipate generating revenues from product sales in the foreseeable future.
	The Company is subject to risks common to companies in the biotechnology industry and the future success of the company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, managing the growth of the organization, obtaining additional financing necessary in order launch and commercialize its product candidates, and competing successfully with other companies in its industry.

Significant_Accounting_Policie

Significant Accounting Policies (Notes)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies	SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been omitted. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position and its results of operations and its cash flows for the periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company’s Annual Report on Form 10-K filed for the fiscal year ended December 31, 2014 (the Annual Report). A copy of the Annual Report is available on the SEC’s website, www.sec.gov, under the Company’s ticker symbol (BLCM) or on Bellicum’s website, www.bellicum.com. The results for the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period. Any reference in these footnotes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).
	Use of Estimates
	The preparation of the financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.
	Historically, prior to the Company’s initial public offering of its common stock, or IPO, in December 2014, the fair values of the shares of common stock underlying the Company’s share-based awards were estimated on each grant date by its Board of Directors. Given the absence of a public trading market for the Company’s common stock, its Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of its common stock, including the following:
	•	its stage of development;
	•	its operational and financial performance;
	•	the nature of its services and its competitive position in the marketplace;
	•	the value of companies that it considers peers based on a number of factors, including similarity to the Company with respect to industry and business model;
	•	the likelihood of achieving a liquidity event, such as an initial public offering and the nature and history of its business;
	•	issuances of preferred stock and the rights, preferences, and privileges of its preferred stock relative to those of its common stock;
	•	business conditions and projections;
	•	the history of the Company and progress of its research and development efforts and clinical trials; and
	•	the lack of marketability of its common stock.
	Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders
	Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of share of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share of common stock is the same as basic net loss per share of common stock, since the effects of potentially dilutive securities are antidilutive. The net loss per share of common stock attributable to common stockholders is computed using the two-class method required for participating securities. All series of the Company’s convertible preferred stock were considered to be participating securities as they were entitled to participate in undistributed earnings with shares of common stock. Due to the Company’s net loss, there is no impact on the earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
	The following outstanding shares of common stock equivalents were excluded from the computations of diluted net loss per shares of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.
	Common Stock Equivalents:	March 31, 2015	March 31, 2014
	Series A Preferred Stock Convertible Preferred Stock - as converted to common stock	—	1,496,782
	Series B Preferred Stock Convertible Preferred Stock - as converted to common stock	—	4,791,740
	Warrants to purchase common stock	355,392	473,031
	Options to purchase common stock	3,443,011	1,584,692
		3,798,403	8,346,245

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments (Notes)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	FAIR VALUE OF FINANCIAL INSTRUMENTS
	ASC 820, Fair Value Measurement, provides a comprehensive framework for measuring the fair value of assets and liabilities, which provides for consistency in how fair value determinations are made under various existing accounting standards that permit, or in some cases require, estimates of fair market value.
	Financial assets and liabilities that have recurring fair value measurements are shown below (in thousands):
		Balance at		Quoted prices in active		Significant other		Significant unobservable
		March 31, 2015		markets for identical		observable inputs		inputs (Level 3)
				assets (Level 1)		(Level 2)
	Assets:
	Money market funds	$	181,636	$	181,636	$	—	$	—
	Total	$	181,636	$	181,636	$	—	$	—
		Balance at		Quoted prices in active		Significant other		Significant unobservable
		December 31, 2014		markets for identical		observable inputs		inputs (Level 3)
				assets (Level 1)		(Level 2)
	Assets:
	Money market funds	$	43,587	$	43,587	$	—	$	—
	Total	$	43,587	$	43,587	$	—	$	—

Accrued_Expenses_Notes

Accrued Expenses (Notes)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
Accrued Expenses	ACCRUED EXPENSES
	Accrued liabilities consist of the following (in thousands):
		31-Mar-15		31-Dec-14
	Accrued payroll	$	—	$	731
	Commission on exercise of warrants	—		731
	Medical facility fees	559		201
	Patient treatment costs	125		128
	License costs	52		50
	Other	343		322
	Total accrued expenses	$	1,079	$	2,163

Stockholders_Equity_Notes

Stockholders' Equity (Notes)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	STOCKHOLDERS' EQUITY
	Preferred Stock
	As of March 31, 2015 and December 31, 2014, the Company had 10,000,000 authorized shares of preferred stock, with none outstanding and a par value of $0.01 per share.
	Common Stock
	As of March 31, 2015 and December 31, 2014, the Company had 200,000,000 authorized shares of common stock with a par value of $0.01 per share.
	Exercise of Common Warrants
	In March 2014, the Company issued 393,523 shares of common stock for $200,700, or $0.51 per share in conjunction with the exercise of warrants expiring in March of 2014.
	Reverse Stock Split
	On December 4, 2014, the Company’s board of directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a reverse split of shares of the Company’s common stock on a 1-for-1.7 basis (the Reverse Stock Split). The par value and the authorized shares of the common stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common stock, options for common stock, warrants for common stock, and per share amounts contained in the financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.

ShareBased_Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation	SHARE-BASED COMPENSATION
	At March 31, 2015, the Company had share-based awards under four share-based compensation plans as follows:
	The 2006 Stock Option Plan (the 2006 Plan) provided for the issuance of non-qualified stock options to employees, including officers, non-employee directors and consultants to the Company. As of March 31, 2015, 161,174 shares of Common Stock were reserved for issuance pursuant to outstanding options previously granted under the 2006 Plan to purchase Common Stock of the Company. The 2006 Plan was terminated by the Board in October 2014.
	The 2011 Stock Option Plan (the 2011 Plan) provided for the issuance of incentive and non-qualified stock options to employees, including officers, non-employee directors and consultants to the Company. As of March 31, 2015, 2,425,561 shares of Common Stock were reserved for issuance pursuant to outstanding options previously granted under the 2011 Plan to purchase Common Stock of the Company. The 2011 Plan terminated upon the effectiveness of the 2014 Plan described below.
	The 2014 Equity Incentive Plan (the 2014 Plan) became effective in December 2014, upon the closing of our initial public offering. The 2014 Plan provides for the issuance of equity awards, including incentive and non-qualified stock options and restricted stock awards to employees, including officers, non-employee directors and consultants to the Company or its affiliates. The 2014 Plan also provides for the grant of performance cash awards and performance-based stock awards. The aggregate number of shares of Common Stock that are authorized for issuance under the 2014 Plan is 2,990,354 shares, plus any shares subject to outstanding options that were granted under the 2011 Plan or 2006 Plan that are forfeited, terminated, expired or are otherwise not issued.
	The 2014 Employee Stock Purchase Plan (ESPP) provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase our Common Stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to 550,000 shares of our Common Stock, pursuant to purchase rights granted to our employees. The ESPP was approved by the Board and our stockholders in December 2014 and employee payroll deductions of approximately $101,000 were withheld during the first quarter of 2015. During the three months ended March 31, 2015, no stock purchases were made under the ESPP and therefore there was no share-based compensation cost. The Company expects to record share-based compensation expense in the future to the extent that shares are purchased for less than fair market value under the ESPP.
	Share-based compensation expense is included within operating expenses as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development	$	599		$	66
	General and administrative	890			10
	Total share-based compensation	$	1,489		$	76
	The Company granted options to purchase 10,293 shares of its common stock during the three months ended March 31, 2014. The fair value of the option grants during the three months ended March 31, 2015 and 2014 was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected volatility	91.2	%	101	%
	Expected term (in years)	6.08		6.25
	Risk-free interest rate	1.6	%	2.7	%
	Expected dividend yield	—	%	—	%
	At March 31, 2015, there was $28.9 million of unrecognized compensation expense related to unvested stock options and stock that is expected to be recognized over a weighted-average period of 3.7 years.
	During the three months ended March 31, 2015, the company received cash proceeds from the exercise of stock options of approximately $2,000. The aggregate intrinsic value of options exercised during the three months ended March 31, 2015 was $0.1 million.
	The following table summarizes the stock option activity for all stock plans during the three months ended March 31, 2015:
		Options		Weighted-			(in years)	(in thousands)
				Average
				Exercise			Weighted-	Aggregate
				Price			Average	Intrinsic
				Per Share			Contractual	Value (1)
							Life
	Outstanding at December 31, 2014	2,733,793		$	5.09		8.39	$	49,076
	Granted	715,100		$	23.7
	Exercised	(5,882	)	$	0.34
	Canceled or forfeited	—		$	—
	Outstanding at March 31, 2015	3,443,011		$	8.96		8.53	$	49,297
	Exercisable at March 31, 2015	1,294,072		$	2.3		6.91	$	26,299
	(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2015.
	At March 31, 2015 and December 31, 2014, there were 117,647 shares of unvested common stock outstanding.

Grant_Revenue

Grant Revenue	3 Months Ended
	Mar. 31, 2015
Grant Revenue [Abstract]
Grant Revenue	GRANT REVENUE
	CPRIT Grant
	On July 27, 2011, the Company entered into a Cancer Research Grant Contract (Grant Contract) with the Cancer Prevention and Research Institute of Texas (CPRIT) under which CPRIT awarded a grant not to exceed approximately $5.7 million to be used by the Company for the execution of defined clinical development of BPX-501. In addition, CPRIT could award supplemental funding not to exceed ten percent of the total grant amount based upon the Company’s progress. The Grant Contract terminated on June 30, 2014. The terms of the Grant Contract require the Company to pay tiered royalties on revenues from sales and licenses of intellectual property facilitated by the Grant Contract.
	During the three months ended March 31, 2014, the Company incurred $0.5 million of expenses under the Grant Contract. As of March 31, 2015 and December 31, 2014, the Company had an outstanding grant receivable of $- million and $0.3 million respectively, for grant expenditures that were paid but had not yet been reimbursed.
	NIH Grant
	During 2014 and 2013, the Company was awarded $0.3 million and $0.4 million, respectively, under a grant from the National Institutes of Health (NIH). The awards cover the period from April 2013 through March 2015. The awards were made pursuant to the authority of 42 USC 241 42 CFR 52, and is subject to the requirements of the statute. Funds spent on the grant are reimbursed through monthly reimbursement requests.
	As of March 31, 2015 and 2014, funds spent under the grant were $0.1 million each. As of March 31, 2015 and December 31, 2014, the Company had a receivable of $0.1 million and $- million, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments Contingencies and Guarantees [Text Block]	COMMITMENTS AND CONTINGENCIES
	Litigation
	The Company, from time to time, may be involved in litigation relating to claims arising out of its ordinary course of business. Management believes that there are no material claims or actions pending or threatened against the Company.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS
	The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.
	New Lease Agreement
	On May 6, 2015, the Company entered into a Lease Agreement (the Lease) with Sheridan Hills Developments L.P. (the Landlord) for the lease of three spaces of approximately 25,304 square feet (the Manufacturing Space), 705 square feet (the Interior Mechanical Space) and 808 square feet (the Exterior Mechanical Space), respectively, which the Company will use to enable in-house cell therapy manufacturing. The term of the Lease will begin on September 1, 2015 and continue for an initial term of five years, which may be renewed for five additional one-year periods. For the Manufacturing Space, the Company is required to remit base monthly rent of approximately $64,841 which will increase at an average approximate rate of 3.5% each year. For the Interior Mechanical Space, the Company is required to remit base monthly rent of approximately $1,219, which will increase at an average approximate rate of 5% each year. The monthly base rent for the Exterior Mechanical Space is approximately $471. The Company is also required to pay additional rent in the form of its pro rata share of certain specified operating expenses of the Landlord. An early termination right is available to the Company upon certain events, including the Landlord’s default on its obligations under the Lease. The newly leased spaces are located within the same building as the Company’s current headquarters in Houston, Texas.
	License Agreement
	On April 23, 2015, the Company and Academisch Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre (Leiden), entered into a license agreement (the Agreement), pursuant to which Leiden granted to the Company an exclusive, worldwide license to its patent rights covering high affinity T-cell receptors targeting PRAME and POU2AF1 epitopes.
	The license granted under the Agreement is subject to certain restrictions and to Leiden’s retained right to use the licensed patents solely for academic research and teaching purposes, including research collaborations by Leiden with academic, non-profit research third parties; provided that Leiden provides 30 days advance written notice to the Company of such academic research collaborations.
	As consideration for the rights granted to the Company under the Agreement, the Company agreed to pay to Leiden an aggregate of EUR 75,000 in upfront fees within 30 days of the effective date of the Agreement. In addition, the Company agreed to pay to Leiden, beginning on the eighth anniversary of the effective date of the Agreement, annual minimum royalty payments of EUR 30,000. The Company also is required to make milestone payments to Leiden of up to an aggregate of EUR 1,025,000 for each of the first licensed product that is specific to PRAME and to POU2AF1. The Agreement additionally provides that the Company will pay to Leiden a royalty in the low single digits on net
	sales of products covered by the Agreement. If the Company enters into a sublicensing agreement with a third party related to a product covered by the Agreement, the Company agreed to pay Leiden a percentage ranging in the low double digits on all non-royalty income received from sublicensing revenue directly attributable to the sublicense, dependent on whether the Company is in phase 1/2, phase 2 or phase 3 at the time that the Company enters into any such sublicensing agreement.
	Under the Agreement, the Company and Leiden also agreed to enter into a sponsored research agreement, to be separately negotiated, pursuant to which the Company would be required to pay Leiden up to EUR 300,000over a three-year period during the term of the sponsored research agreement.
	The Agreement will expire upon the expiration of the last patent included in the licensed patent rights. The Agreement may be terminated earlier upon mutual written agreement between the Company and Leiden, and at any time by the Company upon six months written notice to Leiden. Leiden may terminate the Agreement in the event of a failure by the Company to pay any amounts due under the Agreement that remains uncured on the date that is 30 days after written notice of such failure. Either party may terminate the Agreement upon a material breach by the other party that remains uncured following 30 days after the date of written notice of such breach or upon certain insolvency events that remain uncured following the date that is 45 days after the date of written notice to a party of such insolvency event.
	The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than those disclosed in this Report on Form 10-Q and as discussed in these notes to the financial statements.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been omitted. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position and its results of operations and its cash flows for the periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company’s Annual Report on Form 10-K filed for the fiscal year ended December 31, 2014 (the Annual Report). A copy of the Annual Report is available on the SEC’s website, www.sec.gov, under the Company’s ticker symbol (BLCM) or on Bellicum’s website, www.bellicum.com. The results for the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period. Any reference in these footnotes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).
Use of Estimates	Use of Estimates
	The preparation of the financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.
	Historically, prior to the Company’s initial public offering of its common stock, or IPO, in December 2014, the fair values of the shares of common stock underlying the Company’s share-based awards were estimated on each grant date by its Board of Directors. Given the absence of a public trading market for the Company’s common stock, its Board of Directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of its common stock, including the following:
	•	its stage of development;
	•	its operational and financial performance;
	•	the nature of its services and its competitive position in the marketplace;
	•	the value of companies that it considers peers based on a number of factors, including similarity to the Company with respect to industry and business model;
	•	the likelihood of achieving a liquidity event, such as an initial public offering and the nature and history of its business;
	•	issuances of preferred stock and the rights, preferences, and privileges of its preferred stock relative to those of its common stock;
	•	business conditions and projections;
	•	the history of the Company and progress of its research and development efforts and clinical trials; and
	•	the lack of marketability of its common stock.
Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders	Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders
	Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of share of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share of common stock is the same as basic net loss per share of common stock, since the effects of potentially dilutive securities are antidilutive. The net loss per share of common stock attributable to common stockholders is computed using the two-class method required for participating securities. All series of the Company’s convertible preferred stock were considered to be participating securities as they were entitled to participate in undistributed earnings with shares of common stock. Due to the Company’s net loss, there is no impact on the earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
	The following outstanding shares of common stock equivalents were excluded from the computations of diluted net loss per shares of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Earnings Per Share, Potentially Dilutive Securities	The following outstanding shares of common stock equivalents were excluded from the computations of diluted net loss per shares of common stock attributable to common stockholders for the periods presented as the effect of including such securities would be anti-dilutive.
	Common Stock Equivalents:	March 31, 2015	March 31, 2014
	Series A Preferred Stock Convertible Preferred Stock - as converted to common stock	—	1,496,782
	Series B Preferred Stock Convertible Preferred Stock - as converted to common stock	—	4,791,740
	Warrants to purchase common stock	355,392	473,031
	Options to purchase common stock	3,443,011	1,584,692
		3,798,403	8,346,245

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping	Financial assets and liabilities that have recurring fair value measurements are shown below (in thousands):
		Balance at		Quoted prices in active		Significant other		Significant unobservable
		March 31, 2015		markets for identical		observable inputs		inputs (Level 3)
				assets (Level 1)		(Level 2)
	Assets:
	Money market funds	$	181,636	$	181,636	$	—	$	—
	Total	$	181,636	$	181,636	$	—	$	—
		Balance at		Quoted prices in active		Significant other		Significant unobservable
		December 31, 2014		markets for identical		observable inputs		inputs (Level 3)
				assets (Level 1)		(Level 2)
	Assets:
	Money market funds	$	43,587	$	43,587	$	—	$	—
	Total	$	43,587	$	43,587	$	—	$	—

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Accrued Expenses [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands):
		31-Mar-15		31-Dec-14
	Accrued payroll	$	—	$	731
	Commission on exercise of warrants	—		731
	Medical facility fees	559		201
	Patient treatment costs	125		128
	License costs	52		50
	Other	343		322
	Total accrued expenses	$	1,079	$	2,163

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Allocation of Recognized Period Costs	Share-based compensation expense is included within operating expenses as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development	$	599		$	66
	General and administrative	890			10
	Total share-based compensation	$	1,489		$	76
Valuation Assumptions	The fair value of the option grants during the three months ended March 31, 2015 and 2014 was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected volatility	91.2	%	101	%
	Expected term (in years)	6.08		6.25
	Risk-free interest rate	1.6	%	2.7	%
	Expected dividend yield	—	%	—	%
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the stock option activity for all stock plans during the three months ended March 31, 2015:
		Options		Weighted-			(in years)	(in thousands)
				Average
				Exercise			Weighted-	Aggregate
				Price			Average	Intrinsic
				Per Share			Contractual	Value (1)
							Life
	Outstanding at December 31, 2014	2,733,793		$	5.09		8.39	$	49,076
	Granted	715,100		$	23.7
	Exercised	(5,882	)	$	0.34
	Canceled or forfeited	—		$	—
	Outstanding at March 31, 2015	3,443,011		$	8.96		8.53	$	49,297
	Exercisable at March 31, 2015	1,294,072		$	2.3		6.91	$	26,299
	(1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at March 31, 2015.

Significant_Accounting_Policie3

Significant Accounting Policies Common Stock Equivalents (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,798,403	8,346,245
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	355,392	473,031
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	1,496,782
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	4,791,740
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,443,011	1,584,692

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Money Market Funds, at Carrying Value	$181,636	$43,587
Assets, Fair Value Disclosure	181,636	43,587
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Money Market Funds, at Carrying Value	181,636	43,587
Assets, Fair Value Disclosure	181,636	43,587
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Money Market Funds, at Carrying Value	0	0
Assets, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Money Market Funds, at Carrying Value	0	0
Assets, Fair Value Disclosure	$0	$0

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]
Accrued payroll	$0	$731
Commission on exercise of warrants	0	731
Medical facility fees	559	201
Patient treatment costs	125	128
License costs	52	50
Other	343	322
Total accrued expenses	$1,079	$2,163

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	0 Months Ended	1 Months Ended
	Dec. 04, 2014	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Stockholders' Equity Attributable to Parent [Abstract]
Preferred Stock, Shares Authorized			10,000,000	10,000,000
Preferred Stock, Shares Outstanding			0	0
Preferred Stock, Par or Stated Value Per Share			$0.01	$0.01
Common stock, authorized (shares)			200,000,000	200,000,000
Common stock, par value (usd per share)			$0.01	$0.01
Coomon stock issued in exercise of warrants, shares		393,523
Common stock issued in exercise of warrants, value		$200,700
Common stock issued in exercise of warrants, per share		$0.51
Stockholders' Equity, Reverse Stock Split	1-for-1.7 basis

ShareBased_Compensation_Narrat

Share-Based Compensation Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Share-based Compensation Plans	4
Granted (shares)	715,100	10,293
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$28,900,000
Number of shares available for grant	550,000
Employee stock purchase plan cash contributions	101,000
Stock issued during period, shares, employee stock purchase plans	0
Equity instruments other than options, nonvested	117,647		117,647
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 8 months 12 days
Employee Service Share-based Compensation, Cash Received from Exercise of Stock Options	2,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$100,000
2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	161,174
2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,425,561
2014 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	2,990,354

ShareBased_Compensation_Costs_

Share-Based Compensation Costs Recognized (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$1,489	$76
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	599	66
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$890	$10

ShareBased_Compensation_Valuat

Share-Based Compensation Valuation Assumptions (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	91.20%	101.00%
Expected term (in years)	6 years 29 days	6 years 3 months
Risk-free interest rate	1.60%	2.70%
Expected dividend yield	0.00%	0.00%

ShareBased_Compensation_Stock_

Share-Based Compensation Stock Option Activity (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Options
December 31, 2014 (shares)	2,733,793
Granted (shares)	715,100	10,293
Exercised (shares)	-5,882
Canceled or forfeited (shares)	0
Outstanding at March 31, 2015 (shares)	3,443,011		2,733,793
Exercisable at March 31, 2015 (shares)	1,294,072
Weighted- Average Exercise Price Per Share
December 31, 2014 (usd per share)	$5.09
Granted (usd per share)	$23.70
Exercised (usd per share)	$0
Canceled or forfeited (usd per share)	$0.34
Outstanding at March 31, 2015 (usd per share)	$8.96		$5.09
Exercisable at March 31, 2015 (usd per share)	$2.30
Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Term, Outstanding	8 years 6 months 11 days		8 years 4 months 21 days
Weighted Average Remaining Contractual Term, Exercisable	6 years 10 months 28 days
Aggregate Intrinsic Value, Outstanding	$49,297		$49,076
Aggregate Intrinsic Value, Exercisable	$26,299

Grant_Revenue_Details

Grant Revenue (Details) (USD $)	3 Months Ended		0 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 27, 2011	Dec. 31, 2014	Dec. 31, 2013
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants	$107,000	$552,000
Cancer Prevention and Research Institute of Texas [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants			5,700,000
Percentage of grant			0.1
Costs and expenses		500,000
Grants receivable	0			300,000
National Institutes of Health Grant [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue from grants				300,000	400,000
Costs and expenses	100,000	100,000
Grants receivable	$100,000			$0

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event [Member])	0 Months Ended
	Apr. 23, 2023	6-May-15
	EUR (€)	USD ($)
		Location
		sqft
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of spaces in manufacturing area		3
Number of square feet of manufacturing space		25,304
Number of square feet of exterior mechanical space		705
Number of square feet of interior mechanical space		808
Operating lease, term of contract		5 years
Additional lease renewal periods		1 year
Lease monthly rent amount		$64,841
Average lease rent percentage annual increase		3.50%
Lease monthly rent amount - interior mechanical space		1,219
Annual lease rent percentage annual increase on interior mechanical space		5.00%
Lease monthly rent amount - exterior mechanical space		471
License agreement advance notice of research collaborations	30 days
License costs for rights granted under agreement	75,000
License agreement upfront fee period	30 days
Minimum annual royalty payments beginning on eighth anniversary	30,000
Milestone payments for first licensed products	1,025,000
License agreement sponsored research	€ 300,000
Term of payments under sponsored research agreement	3 years
License agreement termination notice	6 months
License agreement period of notice of failure on uncured items	30 days
License agreement termination period after written notice of failure	30 days
License agreement period after insolvency event	45 days

Uncategorized_Items

Uncategorized Items	12/31/13	12/31/14
	USD ($)	USD ($)
[us-gaap_CashAndCashEquivalentsAtCarryingValue]	11,168,000	191,602,000